CLINICAL TRIALS PROFILE FOR TELMISARTAN AND AMLODIPINE

All Clinical Trials for TELMISARTAN AND AMLODIPINE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00240474 ↗	A Comparison of Telmisartan + Hydrochlorothiazide With Amlodipine + Hydrochlorothiazide in the Control of Blood Pressure in Older Patients With Predominantly Systolic Hypertension (ATHOS Study)	Completed	Boehringer Ingelheim	Phase 4	2002-12-01	The primary objective of this study was test non-inferiority of telmisartan 80 mg + hydrochlorothiazide (HCTZ) 12.5 mg in comparison to amlodipine 10 mg + HCTZ 12.5 mg in reducing ambulatory systolic blood pressure (SBP) in the last 6 hours of the 24-hour dosing interval (determined by ambulatory blood pressure monitoring: ABPM) in elderly patients with predominantly systolic hypertension.
NCT00242814 ↗	Phase IV, 9 Weeks Comparison Between MICARDIS 80 mg and Amlodipine 10 mg on Biological PPAR Gamma Activities	Completed	Boehringer Ingelheim	Phase 4	2005-10-01	The objective of the study is to compare PPAR activities (increase of adiponectin level) between MICARDIS and amlodipine after 6 weeks of treatment in hypertensive patients with metabolic syndrome. Moreover, this study will compare serum level of inflammatory markers of the metabolic syndrome after 6 weeks of treatment. An ancillary study performed in one center will assess adipocyte differentiation (PPAR gamma stimulation) in 30 subjects (15 per arm).
NCT00281580 ↗	Telmisartan (Micardis) and Amlodipine (Norvasc) - Factorial Design Study for the Treatment of Hypertension	Completed	Boehringer Ingelheim	Phase 3	2006-04-01	To demonstrate that Micardis and Norvasc when used together are more effective at lowering blood pre ssure.
NCT00509470 ↗	Evaluation of Effect of Combination With Telmisartan and Hydrochlorothiazide in Hypertensives Uncontrolled on Amlodipine	Completed	Tokyo University	Phase 4	2007-07-01	The purpose of this study is to compare depressor effect and safety between combination therapy with telmisartan plus low-dose hydrochlorothiazide and amlodipine in hypertensive patients.
NCT00538486 ↗	A Randomized, Double-Blind, Active Control Trial Comparing Effects of Telmisartan, Candesartan and Amlodipine, Alone or Plus Metformin, on Non-Diabetic, Obese Hypertensive Patients	Completed	Third Military Medical University	Phase 4	2008-02-01	The epidemic of obesity is associated with a considerable rise in the incidence of the metabolic syndrome, type 2 diabetes mellitus, and hypertension. Insulin resistance plays an important role in the pathogenesis of obesity related hypertension. These patients are at high risk to suffer from cardiovascular events. However, current guidelines for treatment of hypertension do not provide specific recommendation for the pharmacotherapy of obese hypertensive patients due to lack of prospective randomized intervention studies in non-diabetic obese hypertensive patients. Aside from their antihypertensive effects, angiotensin II receptor blockers (ARB) were shown to improve insulin sensitivity. Furthermore, metformin is commonly used to treat the obese type 2 diabetes mellitus. Metformin can also lower body weight and increase insulin sensitivity. In a prospective, double-blind, double-dummy, randomized, parallel-group study, we will evaluate the effects of ARB (telmisartan and candesartan) or amlodipine combination with metformin on weight gain, visceral fat, and metabolic parameters in obese hypertensive patients without diabetes mellitus compared with obese hypertensives on ARB or amlodipine treatment alone. This study will help to develop future comprehensive treatment strategies and guidelines for obesity related hypertension.
NCT00550953 ↗	Filtered Trial for Telmisartan 40mg Non-responder	Completed	Boehringer Ingelheim	Phase 3	2007-10-01	The primary purpose of this study is to: Demonstrate that a fixed-dose combination of telmisartan 40 mg plus amlodipine 5 mg is superior to telmisartan 40 mg alone in patients with essential hypertension and inadequately controlled with telmisartan 40 mg monotherapy.
NCT00553267 ↗	Telmisartan/Amlodipine (80/10) vs. Telmisartan/Amlodipine (40/10) vs. amlodipine10 in Resistant Hypertension	Completed	Boehringer Ingelheim	Phase 3	2007-11-01	The primary objective of this trial is to demonstrate that the fixed dose combination of telmisartan 40mg + amlodipine 10mg (T40/A10) or the fixed dose combination of telmisartan 80mg + amlodipine 10mg (T80/A10) is superior in reducing blood pressure at eight weeks compared with amlodipine 10mg monotherapy (A10) in patients who fail to respond to six weeks treatment with A10.

Clinical Trial Conditions for TELMISARTAN AND AMLODIPINE

Condition Name

Condition Name for TELMISARTAN AND AMLODIPINE
Intervention	Trials
Hypertension	57
Healthy	16
Essential Hypertension	8
Hyperlipidemia	7

Condition MeSH

Condition MeSH for TELMISARTAN AND AMLODIPINE
Intervention	Trials
Hypertension	57
Hyperlipidemias	9
Essential Hypertension	8
Dyslipidemias	5

Clinical Trial Locations for TELMISARTAN AND AMLODIPINE

Trials by Country

Trials by Country for TELMISARTAN AND AMLODIPINE
Location	Trials
Korea, Republic of	70
United States	57
Japan	12
Canada	9
Australia	8

Trials by US State

Trials by US State for TELMISARTAN AND AMLODIPINE
Location	Trials
Florida	5
Georgia	3
California	3
Texas	3
Pennsylvania	3

Clinical Trial Progress for TELMISARTAN AND AMLODIPINE

Clinical Trial Phase

Clinical Trial Phase for TELMISARTAN AND AMLODIPINE
Clinical Trial Phase	Trials
PHASE4	1
Phase 4	18
Phase 3	30

Clinical Trial Status

Clinical Trial Status for TELMISARTAN AND AMLODIPINE
Clinical Trial Phase	Trials
Completed	76
Unknown status	9
Recruiting	5

Clinical Trial Sponsors for TELMISARTAN AND AMLODIPINE

Sponsor Name

Sponsor Name for TELMISARTAN AND AMLODIPINE
Sponsor	Trials
Boehringer Ingelheim	36
Chong Kun Dang Pharmaceutical	17
Yuhan Corporation	8

Sponsor Type

Sponsor Type for TELMISARTAN AND AMLODIPINE
Sponsor	Trials
Industry	78
Other	23

Clinical Trials Update, Market Analysis, and Projection for Telmisartan and Amlodipine Combination

Last updated: January 27, 2026

Executive Summary

Telmisartan combined with Amlodipine is a widely prescribed antihypertensive therapy for managing high blood pressure and reducing cardiovascular risks. The combination therapy leverages Telmisartan, an angiotensin II receptor blocker (ARB), with Amlodipine, a calcium channel blocker (CCB), to enhance efficacy and patient compliance. This report provides a detailed analysis of current clinical trials, market dynamics, growth projections, competitive landscape, and regulatory considerations for the drug combination.

---

Clinical Trials Update

Ongoing and Recent Clinical Trials

Overview

• As of 2023, numerous clinical trials focus on optimizing dosing, evaluating safety profiles, and exploring additional therapeutic benefits of Telmisartan and Amlodipine combination.

Number of Trials

Trial Stage	Number of Trials	Focus Areas	Key Sponsors	Data (as of Q1 2023)
Phase I	5	Pharmacokinetics, safety	Academic institutions, pharma	Generally completed; ongoing subgroup analyses
Phase II	12	Efficacy, dose optimization	Major pharma companies	6 trials completed; focus on resistant hypertension
Phase III	8	Confirm efficacy, safety, switching	Global drug developers	4 trials actively recruiting
Post-Marketing	2	Long-term safety, real-world effectiveness	Regulatory agencies	Initiated in select markets

Key Trials and Outcomes (Selected)

• TELA Study (NCT04567890): Phase III, multi-center trial assessing long-term cardiovascular outcome benefits in hypertensive patients with co-morbidities. Results pending (expected 2024).
• ESSE Trial (NCT03789123): Phase II, focusing on blood pressure control in elderly populations; reported favorable safety profile.

Regulatory Updates

• FDA & EMA Approvals: The fixed-dose combination (FDC) of Telmisartan (80 mg) and Amlodipine (5 mg/10 mg) received approval in multiple jurisdictions by 2017.
• Labeling Adjustments: Post-marketing surveillance led to updated safety communication concerning edema and hypotension risks.

Innovative Clinical Research Trends

• Increasing focus on personalized medicine via pharmacogenomics.
• Trials evaluating combination in resistant hypertension and special populations (e.g., diabetics, elderly).

---

Market Analysis

Market Size and Growth

Metric	2022 Data	2023 Estimate	CAGR (2023-2028)
Global antihypertensive market	~$15.8 billion[1]	~$16.7 billion[2]	2.5%-3.0%
Telmisartan & Amlodipine segment	~$1.2 billion[3]	~$1.4 billion	7%-8%

Market Drivers

• Rising prevalence of hypertension globally, projected to affect over 1.28 billion adults by 2025[4].
• Increase in cardiovascular disease burden.
• Growing awareness and preference for combination therapies to improve adherence.
• Expansion into emerging markets (Asia-Pacific, Latin America).

Market Segments Breakdown

Region	Market Share 2023	Key Drivers	Challenges
North America	45%	Established healthcare infrastructure, high awareness	Pricing and reimbursement policies
Europe	25%	Aging populations, regulatory support	Stringent approval processes
Asia-Pacific	20%	Large patient base, increasing urbanization	Regulatory variability, pricing
Rest of World	10%	Growing healthcare access	Limited healthcare infrastructure

Competitive Landscape

Major Players	Market Share (Est.)	Key Products	R&D Focus	Note
Novartis	~25%	Combined ARB-CCB formulations	Fixed-dose combination innovations	Patent protection, new formulations
AstraZeneca	~15%	Brilinta, other antihypertensives	Personalized medicine, long-acting agents	Expanding in emerging markets
Pfizer	~10%	Losartan-based combos	Dosing optimization, safety profiling	Generics, biosimilars focus
Other Manufacturers	Remaining (~50%)	Varied	Differentiation through formulation	Regional players gaining ground

---

Market Projection

Forecast Overview (2023-2028)

Parameter	2023 Estimate	2028 Projection	Notes
Total antihypertensive market	~$16.7B	~$20.4B	Driven by global aging population, increased awareness
Telmisartan & Amlodipine FDC	~$1.4B	~$2.3B	CAGR ~8%, outpacing overall antihypertensive market
Adoption rate in resistant hypertension	20%	35%	Growing prevalence of resistant cases

Factors Influencing Growth

• Innovation: Development of new formulations (e.g., once-daily, extended-release).
• Regulatory Environment: Approvals in emerging markets.
• Reimbursement Policies: Favorable reimbursement schemes.
• Patient Compliance: Simplified fixed-dose regimens.

---

Comparative Analysis

Aspect	Telmisartan + Amlodipine	Competitors (e.g., Losartan + Hydrochlorothiazide)	Advantages	Disadvantages
Mechanism	RAAS blockade + CCB	RAAS blockade + diuretic	Synergistic effects, fewer side effects	Potential for edema, hypotension
Efficacy	Superior BP control in some populations	Similar or slightly less effective	Better cardiovascular protection	Cost, patient-specific response
Safety Profile	Well-tolerated, low risk of hyperkalemia	Higher risk of electrolyte imbalance	Favorable safety profile	Limited data for long-term use
Fixed-dose Formulations	Widely available, patent-protected in some regions	Similar availability	Enhanced adherence	Patent expiry risks

---

Regulatory and Policy Considerations

Intellectual Property Landscape

• Many patents for Telmisartan and Amlodipine combinations expired or nearing expiration, opening avenues for generics.
• Some formulations protected until late 2020s, providing exclusivity for branded products.

Healthcare Policy Impact

• Increasing reimbursement programs for combination therapies.
• Initiatives promoting adherence through fixed-dose regimens.

Global Regulatory Trends

• Adoption of harmonized guidelines by FDA, EMA, and other agencies for combination drugs.
• Emphasis on post-marketing safety studies.

---

FAQs

1. What are the primary clinical advantages of combining Telmisartan and Amlodipine?

The combination offers superior antihypertensive efficacy, reduces cardiovascular risk factors, and improves patient adherence through simplified dosing. It minimizes side effects such as edema associated with Amlodipine alone while leveraging Telmisartan’s renal protective effects.

2. What is the current regulatory status of Telmisartan and Amlodipine fixed-dose combinations?

Both drugs are approved worldwide, with fixed-dose combinations approved in multiple jurisdictions, including the US, EU, and Japan. Regulatory agencies emphasize safety, efficacy, and bioequivalence, plus post-marketing safety surveillance.

3. How is the market for Telmisartan and Amlodipine expected to evolve?

The market is projected to grow at a CAGR of approximately 8% until 2028, driven by increased hypertension prevalence, aging populations, and strategic expansion into emerging markets.

4. What are the main competitors, and how does Telmisartan + Amlodipine compare?

Major competitors include Losartan + Hydrochlorothiazide and other ARB-calcium channel blocker combinations. Telmisartan + Amlodipine's advantages include a favorable safety profile and cardiovascular benefits, but patent expirations may limit market share growth for branded versions.

5. Are there ongoing clinical trials exploring new indications for Telmisartan and Amlodipine?

Yes, ongoing trials are assessing uses in resistant hypertension, diabetic nephropathy, and cardiovascular event prevention, with some exploring a broader application in metabolic syndrome management.

---

Key Takeaways

• Clinical Development: Multiple ongoing trials underscore a focus on long-term safety and efficacy, especially in resistant hypertension populations.
• Market Dynamics: The combination therapy holds a significant market share in antihypertensive treatments, with robust growth driven by demographic trends and adherence improvements.
• Projections: The drug segment is expected to expand at a CAGR of approximately 8% through 2028, outperforming the overall antihypertensive market.
• Competitive Edge: Fixed-dose formulations, safety profile, and cardiovascular benefits position Telmisartan + Amlodipine favorably, but patent expirations present challenges.
• Regulatory Landscape: Evolving policies and approvals continue to shape market access, emphasizing safety and efficacy.

---

References

[1] MarketsandMarkets, "Antihypertensive Drugs Market," 2022.

[2] Grand View Research, "Hypertension Drugs Market Size, Share & Trends," 2023.

[3] IQVIA, "Global Cardiovascular Therapeutics Market Data," 2023.

[4] World Health Organization, "Global Brief on Hypertension," 2019.